GUS
… (≤12 [IV: GUS=43%, PBO=21%; SC: GUS=52%, PBO=24%] and >12 [IV: GUS=53% vs PBO=16%; SC: GUS=62% vs PBO=18%]), baseline CRP (≤3mg/L …
8articles mentioning drugs
113drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: GUS ×
GUS
This drug is selected. Its supporting articles are shown below.
Articles mentioning GUS
8 articles · page 1 of 1GUSGuselkumabazathioprine6-mercaptopurine
…8 pts allocated 1:1:1 to GUS 400 mg SC every 4 weeks (q4w) (×3)→GUS 200 mg SC q4w (N=140), GUS 400 mg SC q4w (×3)→GUS 100 mg SC eve…
GuselkumabGUS
…-23 signaling. Front. Immunol. 2025;16:1532852.Rubin DT, et al. Guselkumab in patients with moderately to severely active ulcerative colit…
GuselkumabGUSUCQUASAR
…Objective Guselkumab (GUS) is a dual-acting IL-23p19 inhibitor that neutralises IL-2…
GUSGuselkumabGRAVITIGALAXICrohn’s diseaseCD
… SC maintenance (100 mg q8w or 200 mg q4w). GRAVITI assessed SC GUS induction (400 mg at W0, W4, and W8) and the same GUS maintenan…
GuselkumabGUSGUS-treatedulcerative colitisJohnson & Johnson
…Introduction Guselkumab (GUS) is a dual-acting IL-23p19 subunit inhibitor that potently…
GUSGuselkumabPBORobarts Histopathology IndexCDCrohn’s disease
…mg SC q4w maintenance vs PBO also achieved histologic response (GUS 100 mg SC q8w 49.5% and GUS 200 mg SC q4w 63.6% vs 10.6% PBO), …
GUSmethotrexate6-mercaptopurineGuselkumabazathioprineperianal fistulizing Crohn’s diseaseperianal fistulizing CDNCT05347095FUZION
… full analysis set, 113 received GUS 100mg SC Q8W, 115 received GUS 200mg SC Q4W, and 58 received PBO. 91.3% completed the 24 weeks…